AstraZeneca completes $2 billion Summit investment. AstraZeneca stock gains 1.56 percent

Published on 10/06/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jefferies kept Buy and a GBp 17,500 target on September 29, 2026. AstraZeneca stock costs EUR 141.68 on October 6, 2026, versus EUR 139.50.

Architektur-Rendering eines gläsernen Biotech-Bürogebäudes mit Wasserbecken — AstraZeneca plc (ISIN GB0009895292) investiert kontinuierlich in nachhaltige, architektonisch anspruchsvolle Firmenzentralen und Forschungsgebäude, Illustration mit AI erstellt.

AstraZeneca (ISIN GB0009895292) was trading at EUR 141.68 at Lang & Schwarz on October 6, 2026 at 12:40 p.m. CEST, up 1.56 percent versus the EUR 139.50 prior close. The company completed a USD 2.00 billion equity investment in Summit Therapeutics on October 5, 2026, according to AstraZeneca.

Summit investment closes

The investment is intended to accelerate ivonescimab, a bispecific antibody targeting PD-1 and VEGF, in combination with antibody drug conjugates across tumor types. AstraZeneca also disclosed a clinical collaboration with Summit and Daiichi Sankyo to evaluate Datroway with ivonescimab in lung and breast cancer studies.

The transaction adds a quantified oncology commitment to AstraZeneca's pipeline strategy. The company said the investment will support combinations involving its own cancer medicines, including additional antibody drug conjugates, rather than functioning as a standalone financial holding.

Research capacity expands in Massachusetts

On October 5, 2026, AstraZeneca opened a strategic research and development center in Kendall Square, Cambridge, Massachusetts. Business Wire reported that the site covers 570,000 square feet and will bring nearly 2,000 researchers and scientists together with an existing genomic medicine location.

The capital commitment sits alongside operating growth. ScanX reported that revenue rose 6.00 percent to USD 14.10 billion in the first half of 2026, while core earnings per share increased 11.00 percent. Management reiterated full-year 2026 guidance for mid- to high-single-digit revenue growth and low-double-digit core earnings-per-share growth.

Stock gains against prior close

AstraZeneca stock's EUR 141.68 Lang & Schwarz price stood EUR 2.18 above the October 5, 2026 prior close, matching the plus 1.56 percent daily move. The gain gives the market a same-day valuation response while the Summit investment and the Massachusetts center add longer-term pipeline and capacity figures.

The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.